Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.

ABSTRACT:

Background

Pyrotinib, an irreversible pan-human epidermal growth (HER) inhibitor, has proven its antitumor efficacy as a second-line treatment for HER2-positive metastatic breast cancer (HER2+ MBC) when combined with capecitabine. However, real-world data concerning the pyrotinib, trastuzumab, and chemotherapy (PyroHC) combination remains scarce.

Objectives

Our study is to report the treatment patterns, efficacy, and safety of the PyroHC combination in a real-world setting.

Design

This study enrolled patients with HER2+ MBC from five institutions in China, treated with PyroHC between June 2017 and January 2023 (ClinicalTrials.gov, identifier: NCT05839288).

Methods

We evaluated progression-free survival (PFS), objective response rate (ORR), toxicity profile, and

SUBMITTER: You S 

PROVIDER: S-EPMC10748899 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature